Fifteen researchers from the Radboud University and Radboud university medical center have been awarded a Veni grant by NWO, the Netherlands Organisation for Scientific Research. These grants of up to €250,000 provide highly promising young scientists with the opportunity to further elaborate their own ideas during a period of three years.Jorik Nonnekes, theme Disorders of movement received a Veni grant for his project: "Towards personalized rehabilitation: understanding compensation strategies for gait impairments in Parkinson’s disease".
Gait impairments are common in Parkinson’s disease. Patients use strategies to compensate for their gait impairments, but these compensation strategies are not effective for every patient and are poorly understood. To improve treatment Nonnekes will investigate their working mechanism, and link patient characteristics to the effectiveness of individual compensation strategies.
15 Veni grants for Radboud researchers: more information in this link.
Related news items
How do we keep new technology affordable to improve the lives of people?16 May 2019
Improving healthcare by means of new technological developments? We need to change the entire approach for evaluating the true impact , says Maroeska Rovers. By bringing together all stakeholders from the beginning, millions of euros can be saved.read more
Dutch Kidney Foundation Innovation grant for Tom Nijenhuis14 May 2019
Tom Nijenhuis, theme Renal disorders, received this grant for his research project “Salt supplementation in Gitelman syndrome: A simple intervention using an innovative N-of-1 trial approach”.read more
Algorithm calculates the presence and aggressiveness of prostate tumors14 May 2019
A computer program that analyzes MRI images can reliably map the presence and even the aggressiveness of a prostate tumor. This is what Radboudumc researchers and international colleagues have published in the scientific journal Investigative Radiology.read more
Universal tumor BRCA1/2 testing of ovarian cancer13 May 2019
Marjolijn Ligtenberg, Janet Vos and Nicoline Hoogerbrugge, assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition testing. They have published their findings in the JNCI.read more